Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%
Regulatory

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

By The Northwire Desk — AI Analysis Dec 22, 2025 · 09:00 QNTM · 12.32 Quantum BioPharma Ltd.
QNTM · Price

Executive Summary

  • Quantum BioPharma disclosed that shareholder Paul Durkacz has filed a class‑action lawsuit alleging stock manipulation affecting investors between Jan 6 2021 and Oct 15 2025.
  • The company intends to seek appointment as lead plaintiff in the action to protect its shareholders.
  • Quantum BioPharma renewed legal services with LWM for one month starting Dec 22 2025 to support the litigation.

Key Details

  • Lawsuit Allegations: Claims that investors who sold Quantum BioPharma securities were “significantly and materially harmed” by alleged manipulation of the stock.
  • Class Action Scope: Covers transactions from 6 Jan 2021 through 15 Oct 2025.
  • Lead Plaintiff Request: Quantum BioPharma will apply to be appointed lead plaintiff, aiming to represent the interests of all affected shareholders.
  • Legal Representation: Services of law firm LWM have been renewed for a one‑month term beginning 22 Dec 2025.
  • Link to Complaint: A copy of the complaint is available via the provided hyperlink in the release.
  • Forward‑Looking Statements: The release contains forward‑looking language regarding potential outcomes, litigation funding, and related risks; these statements are qualified by standard risk disclosures.

Notable Quotes

(No direct quotes were included in the press release.)

Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other